Affiliations 

  • 1 Subang Jaya Medical Centre, 47500 Subang Jaya, Selangor, Malaysia; Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia. Electronic address: drpathma@gmail.com
  • 2 University Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia. Electronic address: cheahpl@ummc.edu.my
  • 3 International Islamic University Malaysia, 25200 Kuantan, Pahang, Malaysia. Electronic address: how_sh@yahoo.com
  • 4 University of Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: liamck@ummc.edu.my
  • 5 Prince Court Medical Centre, 50450 Kuala Lumpur, Malaysia. Electronic address: mazrif@gmail.com
  • 6 Ministry of Health, 62590 Putrajaya, Malaysia. Electronic address: norhayatiomar1973@gmail.com
  • 7 Ministry of Health, 62590 Putrajaya, Malaysia. Electronic address: drnoriah75@yahoo.com
  • 8 Institute of Respiratory Medicine, Kuala Lumpur Hospital, 53000 Kuala Lumpur, Malaysia. Electronic address: nurmm25@gmail.com
  • 9 University Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia. Electronic address: yongkek@gmail.com
  • 10 Ministry of Health, 62590 Putrajaya, Malaysia. Electronic address: rossuzanna@gmail.com
  • 11 Sunway Medical Centre, Selangor, 47500 Petaling Jaya, Selangor, Malaysia. Electronic address: lyetho@gmail.com
Lung Cancer, 2019 10;136:65-73.
PMID: 31446227 DOI: 10.1016/j.lungcan.2019.08.005

Abstract

In the recent years, increased understanding of the molecular profiles of non-small cell lung cancer (NSCLC) has allowed for targeted treatment of actionable genetic mutations. The management of NSCLC now requires multiple molecular tests to guide the treatment strategy. In the light of this, there is a need to establish a molecular testing consensus statement for advanced NSCLC patients in Malaysia. This Malaysian consensus statement was developed by a panel of experts, chaired by a pathologist and composed of three other pathologists, four respiratory physicians and three oncologists. It reflects currently available scientific data and adaptations of recommendations from international guidelines to the local landscape. Expert recommendations on different aspects of molecular testing agreed upon by the panel are provided as structured discussions. These recommendations address the appropriate patients and samples to be tested, as well as when and how these tests should be performed. The algorithms for molecular testing in metastatic NSCLC, in the first line setting and upon disease progression beyond first line therapy, were developed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.